ESMO 2019: Opdivo and Yervoy in the spotlight

19 September 2019
esmo_2018_big-1

Bristol-Myers Squibb (NYSE: BMY) has outlined the data it will present at this year’s annual meeting of the European Society for Medical Oncology (ESMO), in Barcelona, Spain.

The New Jersey, USA-based cancer specialist has data from over 65 studies across 18 tumor types, including new data on immuno-oncology workhorse Opdivo (nivolumab), as well as Opdivo plus Yervoy (ipilimumab).

Of perhaps the most interest will be overall survival (OS) data from Part 1 of the CheckMate-227 study of Opdivo plus low-dose Yervoy in advanced non-small cell lung cancer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology